We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Ultra‐low‐dose rituximab: Alternative treatment for autoimmune dermatological conditions.
- Authors
Reyes‐Soto, Mayra A.; Chavez‐Alvarez, Sonia; Yamallel‐Ortega, Luis A.; Aguilar‐Calderón, Patrizia E.; Perales‐González, Alejandra; Villarreal‐Martínez, Alejandra; Gómez‐Flores, Minerva; Ocampo‐Candiani, Jorge
- Abstract
This article discusses the use of ultra-low-dose rituximab as an alternative treatment for autoimmune dermatological conditions. The authors conducted a study on three patients with different autoimmune skin diseases and found that a regimen of 100mg of rituximab once a week for four weeks resulted in significant improvement without any adverse events. The authors suggest that this low-dose regimen could be a cost-efficient and effective treatment option, especially in countries where rituximab is expensive and not easily accessible. However, more studies are needed to determine the efficacy, safety, and duration of remission for this treatment.
- Subjects
BULLOUS pemphigoid; RITUXIMAB; AUTOIMMUNE hemolytic anemia; PEMPHIGUS vulgaris
- Publication
Journal of the European Academy of Dermatology & Venereology, 2024, Vol 38, Issue 7, pe587
- ISSN
0926-9959
- Publication type
Article
- DOI
10.1111/jdv.19760